Pharmacological interventions for drug-using offenders

Perry, Amanda; Neilson, Matthew; James, Marrissa Martyn-St; Glanville, Julie; McCool, Rachael; Duffy, Steven; Godfrey, Christine; Hewitt, Catherine

doi:10.1002/14651858.cd010862

Cited by 25 publications

(8 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding at first seems to contradict the findings of other systematic reviews which point to a positive effect of pharmacological intervention programs administered outside the prisons (Egli et al, 2009;Perry et al, 2013;Perry et al, 2015). The context within which the intervention takes place can significantly affect the results ).…”

Section: Conclusion and Evaluationcontrasting

confidence: 55%

“…(e) The original evaluation studies must have the following method characteristics: there must be at least one control or comparison group; the control group should be exposed to either no intervention or minimal treatment, and the control group must not include dropouts (people who had previously participated in the treatment program but later left it). Some systematic reviews which did not meet one or more of these criteria could not be included in this study (e.g., Adams, Leukefeld, & Peden, 2008;Bright & Martire, 2013;Egli, Pina, Skovbo Christensen, Aebi, & Killias, 2009;Ferri, Davoli, & Perucci, 2011;Fiestas & Ponce, 2012;Hedrich et al, 2011;Holloway, Bennett, & Farrington, 2005Koehler, Humphreys, Akoensi, Sanchez de Ribera, & Lösel, 2014;Larney, 2010;Mazerolle, Soole, & Rombouts, 2007;McMurran, 2006;Minozzi et al, 2011;Mitchell, Wilson, Eggers, & MacKenzie, 2012;Perry, 2006;Perry, Darwin, et al, 2009;Perry et al, 2013;Perry et al, 2015aPerry et al, , 2015bPerry, Newman, et al, 2009;Tripodi, Bledsoe, Kim, & Bender, 2011;Smedslund et al, 2011;Smith, Gates, & Foxcroft, 2006;Stallwitz & Stöver, 2007).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Prison-based Drug Treatment Programs: A Systematic Review of Meta-analyses

Topçuoğlu¹

2016

addicta

View full text Add to dashboard Cite

Objectives: Drawing upon existing meta-analytic reviews, this paper aims to systematically review the state of research on the effects of prison-based drug treatment programs on drug use and recidivism after imprisonment. Method: A systematic search was carried out through the Cochrane Library, the Campbell Collaboration Library of Systematic Reviews and Google scholar. Results: Based on the eligibility criteria set forth, three meta-analytic studies on the effects of prison-based drug treatment programs on drug use and recidivism were retrieved. All three meta-analyses consistently point to the positive effects of therapeutic communities both on drug use and recidivism. Findings regarding the positive effects of other incarcerationbased drug treatment programs (e.g., counselling, narcotic maintenance programs, etc.) are less clear.Limitations as well as implications of the findings for research, policy and practice in Turkey are discussed.

show abstract

Section: Conclusion and Evaluationcontrasting

confidence: 55%

Section: Methodsmentioning

confidence: 99%

Effectiveness of Prison-based Drug Treatment Programs: A Systematic Review of Meta-analyses

Topçuoğlu¹

2016

addicta

View full text Add to dashboard Cite

show abstract

“…There were significant positive outcomes of treatment on reoffending (d=0.47) and drug use (d=0.38) 61. Using slightly different criteria, a Cochrane review of MAT for offenders with substance misuse found 11 studies met criteria for inclusion; overall results reflect that MAT reduces drug use in this population 62…”

Section: Interventionsmentioning

confidence: 99%

Mental health of prisoners: prevalence, adverse outcomes, and interventions

Fazel

Hayes

Bartellas

et al. 2016

The Lancet Psychiatry

725

613

View full text Add to dashboard Cite

More than 10 million people are imprisoned worldwide, and the prevalence of all investigated mental disorders is higher in prisoners than in the general population. Although the extent to which prison increases the incidence of mental disorders is uncertain, considerable evidence suggests low rates of identification and treatment of psychiatric disorders. Prisoners are also at increased risk of all-cause mortality, suicide, self-harm, violence, and victimisation, and research has outlined some modifiable risk factors. Few high quality treatment trials have been done on psychiatric disorders in prisoners. Despite this lack of evidence, trial data have shown that opiate substitution treatments reduce substance misuse relapse and possibly reoffending. The mental health needs of women and older adults in prison are distinct, and national policies should be developed to meet these. In this Review, we present clinical, research, and policy recommendations to improve mental health care in prisons. National attempts to meet these recommendations should be annually surveyed.

show abstract

“…1 Evidence-based treatments including methadone and buprenorphine are usually unavailable during incarceration, 2,3 and rates of opioid relapse and overdose death are elevated at release. 4 While these medication assisted treatment modalities are associated with improved outcomes, 5,6,7,8,9,10,11 community supervision (i.e., parole, probation) authorities typically discourage their use. 12 In addition, well-known stigmas and prior negative treatment experiences may bias affected individuals from pursuing these medications.…”

Section: Introductionmentioning

confidence: 99%

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial

Lee

Friedmann

Boney

et al. 2015

Contemporary Clinical Trials

View full text Add to dashboard Cite

Background Extended-release naltrexone (XR-NTX, Vivitrol® Alkermes Inc.) is an injectable monthly sustained-release mu opioid receptor antagonist. XR-NTX is a potentially effective intervention for opioid use disorders and as relapse prevention among criminal justice system (CJS) populations. Methods This 5-site open-label randomized controlled effectiveness trial examines whether XR-NTX reduces opioid relapse compared with treatment as usual (TAU) among community dwelling, non-incarcerated volunteers with current or recent CJS involvement. The XR-NTX arm receives 6 monthly XR-NTX injections at Medical Management visits; the TAU group receives referrals to available community treatment options. Assessments occur every 2 weeks during a 24-week treatment phase and at 12- and 18-month follow-ups. The primary outcome is a relapse event, defined as either self-report or urine toxicology evidence of ≥10 days of opioid use in a 28-day (4 week) period, with a positive or missing urine test counted as 5 days of opioid use. Results We describe the rationale, specific aims, and design of the study. Alternative design considerations and extensive secondary aims and outcomes are discussed. Conclusions XR-NTX is a potentially important treatment and relapse prevention option among persons with opioid dependence and CJS involvement.

show abstract

Pharmacological interventions for drug-using offenders

Cited by 25 publications

References 146 publications

Effectiveness of Prison-based Drug Treatment Programs: A Systematic Review of Meta-analyses

Effectiveness of Prison-based Drug Treatment Programs: A Systematic Review of Meta-analyses

Mental health of prisoners: prevalence, adverse outcomes, and interventions

Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial

Contact Info

Product

Resources

About